Berirab P 300IU Injection

Berirab P 300 IU Injection contains the active agent Human Rabies Immunoglobulin (HRIG). It is indicated to prevent passive, transient rabies infection after exposure to a rabid animal (dogs, mongoose, jackals, foxes). This injection is formulated from blood plasma from screened donors. Rabies infection spreads when a person is bitten, scratched, or licked by an infected animal, especially when the skin is already injured. Rabies is a serious and often fatal viral disease that can cause severe neurological symptoms, including fever, headache, muscle weakness, and paralysis. Once symptoms develop, the disease is almost always fatal. Though this infection is 100% fatal, it is 100% preventable with timely measures and the correct use of available vaccines, immunoglobulins, or monoclonal antibodies.

People with a history of severe allergic reactions to Berirab P 300IU Injection or any of its components should not receive this medication. This injection is prepared from human plasma and may contain infectious agents that can cause disease. Report to your physician immediately if you experience symptoms like headache, nausea, fever, vomiting, weakness, muscle pain, or diarrhea, as these symptoms indicate a possible viral infection. Pediatric patients require special considerations regarding the use of Berirab P 300IU Injection. It can be used in elderly individuals, but the dose and administration may need to be adjusted based on age, weight, and health status.